This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CEP-701

Teva Pharmaceutical Industries Ltd.

Drug Names(s): KT-5555

Description: CEP-701 is an orally available, novel, receptor tyrosine kinase inhibitor that inhibits FLT3 autophosphorylation as well as Trk tyrosine kinases.

Deal Structure: CEP-701 was originally developed by Cephalon.

Teva and Cephalon
In May 2011, Teva and Cephalon announced that their Boards of Directors unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The acquisition was closed in October 2011.


CEP-701 News

Pink Sheet Licensing In Brief


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug